Lack of access to medicine is a major driver of drug resistance. How can pharma take action?
The antibiotic market is unstable, with fragile supply chains and tough market conditions. This report sets out how these factors limit the development of a robust go-to-market model for such products. It features six case studies where companies and their partners are using a combination of access strategies to cut through the complexity and address access at a local level.